Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.65 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | YES1 | P07947 | 1/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | HCK | P08631 | 1/20 | 0.65 |
| ▸ | FGR | P09769 | 1/20 | 0.65 |
| ▸ | TEC | P42680 | 1/20 | 0.65 |
| ▸ | TXK | P42681 | 1/20 | 0.65 |
| ▸ | BLK | P51451 | 1/20 | 0.65 |
| ▸ | BMX | P51813 | 1/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860549 | 1.00 | BTK (0.70) | BTKSRCLCKFYNYES1 | |
| SCHEMBL15517353 | 0.90 | BTK (0.69) | BTK | |
| SCHEMBL463456 | 0.84 | BTK (0.75) | BTKLCK | |
| SCHEMBL410260 | 0.84 | BTK (0.75) | BTKLCK | |
| SCHEMBL25591499 | 0.84 | BTK (0.89) | BTKSRCLCKFYNYES1 | |
| SCHEMBL18925740 | 0.84 | BTK (0.53) | BTKSRCLCKFYNYES1 | |
| SCHEMBL18533039 | 0.83 | BTK (0.79) | BTKSRCLCKFYNYES1 | |
| SCHEMBL19731424 | 0.82 | BTK (0.48) | BTKSRC | |
| SCHEMBL19296677 | 0.82 | BTK (0.58) | BTKSRCLCKFYNYES1 | |
| SCHEMBL15516734 | 0.81 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572811-B2 | Treatment of dry eye | PRINCIPIA BIOPHARMA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2710005-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9090621-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150182530-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-8962831-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962635-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957080-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8946241-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2012158795-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | BTK 5/4885SRC 25/4885LCK 14/4885 |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885SRC 18/4885LCK 10/4885 |
| US-20150182530-A1 | TREATMENT OF DRY EYE | BTK, SYK, LYN | BTK 1/4885SRC 8/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.